PL1678166T3 - Inhibitory kinaz białkowych - Google Patents
Inhibitory kinaz białkowychInfo
- Publication number
- PL1678166T3 PL1678166T3 PL04795080T PL04795080T PL1678166T3 PL 1678166 T3 PL1678166 T3 PL 1678166T3 PL 04795080 T PL04795080 T PL 04795080T PL 04795080 T PL04795080 T PL 04795080T PL 1678166 T3 PL1678166 T3 PL 1678166T3
- Authority
- PL
- Poland
- Prior art keywords
- protein kinase
- kinase inhibitors
- disclosed
- cycl1
- cycl2
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51148603P | 2003-10-14 | 2003-10-14 | |
| US51148903P | 2003-10-14 | 2003-10-14 | |
| US60852904P | 2004-09-09 | 2004-09-09 | |
| EP04795080A EP1678166B1 (en) | 2003-10-14 | 2004-10-14 | Protein kinase inhibitors |
| PCT/US2004/033870 WO2005037825A2 (en) | 2003-10-14 | 2004-10-14 | Protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1678166T3 true PL1678166T3 (pl) | 2009-12-31 |
Family
ID=34468370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04795080T PL1678166T3 (pl) | 2003-10-14 | 2004-10-14 | Inhibitory kinaz białkowych |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7326712B2 (pl) |
| EP (1) | EP1678166B1 (pl) |
| JP (1) | JP4845736B2 (pl) |
| AT (1) | ATE437872T1 (pl) |
| AU (1) | AU2004282179B2 (pl) |
| CA (1) | CA2542076C (pl) |
| CY (1) | CY1110504T1 (pl) |
| DE (1) | DE602004022318D1 (pl) |
| DK (1) | DK1678166T3 (pl) |
| ES (1) | ES2344007T3 (pl) |
| PL (1) | PL1678166T3 (pl) |
| PT (1) | PT1678166E (pl) |
| SI (1) | SI1678166T1 (pl) |
| WO (1) | WO2005037825A2 (pl) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| WO2006074147A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| US20080051414A1 (en) * | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| US20090143399A1 (en) * | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| US20090099165A1 (en) * | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| US20070244114A1 (en) * | 2004-07-06 | 2007-10-18 | Myriad Genetics, Incorporated | Compounds and therapeutical use thereof |
| US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| EP1776982A1 (en) * | 2005-10-18 | 2007-04-25 | Argenta Discovery Limited | Pyrimidine compounds as histamine modulators |
| JP2008519794A (ja) * | 2004-11-11 | 2008-06-12 | アージェンタ・ディスカバリー・リミテッド | ピリミジン化合物 |
| US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2604284A1 (en) * | 2005-04-28 | 2006-11-02 | Supergen, Inc. | Protein kinase inhibitors |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| US20070004660A1 (en) * | 2005-06-10 | 2007-01-04 | Baumann Christian A | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US20070004763A1 (en) * | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| US20060281771A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| US20070249640A1 (en) * | 2005-06-16 | 2007-10-25 | Myriad Genetics, Incorporated | Pharmaceutical compositions and use thereof |
| EP1767537A1 (en) * | 2005-09-21 | 2007-03-28 | Cellzome (UK) Ltd. | Pyrimidine compounds for the treatment of inflammatory disorders |
| EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1968596A4 (en) * | 2005-12-22 | 2010-12-01 | Icagen Inc | ANTAGONISTS OF CALCIUM CHANNEL |
| EP1829879A1 (en) * | 2006-02-10 | 2007-09-05 | Cellzome (UK) Ltd. | Amino pyrimidine compounds for the treatment of inflammatory disorders |
| JP2010500283A (ja) * | 2006-05-31 | 2010-01-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法 |
| FR2903387B1 (fr) * | 2006-07-05 | 2008-08-29 | Alcatel Sa | Actionneur pour systemes de guidage d'equipements spatiaux a taux de rotation variable |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008055233A1 (en) * | 2006-10-31 | 2008-05-08 | Supergen, Inc. | Protein kinase inhibitors |
| ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| US7820684B2 (en) | 2007-03-01 | 2010-10-26 | Supergen, Inc. | Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same |
| CA2682733A1 (en) * | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors |
| EP2170886A1 (en) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| WO2009023876A1 (en) * | 2007-08-16 | 2009-02-19 | Myriad Genetics, Inc. | Method of treating non-small cell lung cancer |
| US7960400B2 (en) | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| US7982035B2 (en) * | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| EP2217716A4 (en) * | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS |
| WO2009081222A1 (en) * | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| EP2297153B1 (en) | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Limk2 inhibitors, compositions comprising them, and methods of their use |
| KR101667822B1 (ko) * | 2008-04-30 | 2016-10-19 | 내셔날 헬스 리서치 인스티튜트 | 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물 |
| US20100016247A1 (en) * | 2008-07-21 | 2010-01-21 | Florida State University Research Foundation | Using budding yeast to screen for inhibitors of aurora kinases |
| EP2331530B8 (en) * | 2008-09-26 | 2013-12-25 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| CN102573484B (zh) | 2009-06-09 | 2015-07-01 | 加利福尼亚资本权益有限责任公司 | 苄基取代的三嗪衍生物及其治疗应用 |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CA2765030C (en) | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| CA2771822C (en) | 2009-09-04 | 2020-08-11 | Daniel A. Erlanson | Bruton's tyrosine kinase inhibitors |
| WO2011056739A1 (en) * | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Compounds and methods |
| WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
| CN101857588B (zh) * | 2010-06-08 | 2013-11-27 | 东南大学 | 4-芳香胺基喹唑啉类衍生物及其用途 |
| PH12013501800A1 (en) | 2011-03-15 | 2013-10-14 | L Livermore Nat Security Llc | Tricyclic gyrase inhibitors |
| US20130017163A1 (en) | 2011-07-14 | 2013-01-17 | Latham Keith R | Halogenated phenols for diagnostics, antioxidant protection and drug delivery |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| JP6073910B2 (ja) | 2011-11-09 | 2017-02-01 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用 |
| RS59002B1 (sr) | 2012-01-27 | 2019-08-30 | Univ Montreal | Pirimido[4,5-b]indol derivati i njihova primena u ekspanziji hematopoetskih matičnih ćelija |
| WO2013115167A1 (ja) * | 2012-01-31 | 2013-08-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アムバチニブ誘導体 |
| JP6027230B2 (ja) | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
| CN102690274A (zh) * | 2012-05-24 | 2012-09-26 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氯-2-甲基嘧啶苯并呋喃合成工艺 |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| WO2014043272A1 (en) * | 2012-09-12 | 2014-03-20 | Trius Therapeutics Inc. | Tricyclic gyrase inhibitors for use as antibacterial agents |
| CN102875558A (zh) * | 2012-11-05 | 2013-01-16 | 贵州大学 | 2-氯-4-取代-8-硝基苯并呋喃[3,2-d]嘧啶类化合物及其制备方法和用途 |
| CN104045642B (zh) * | 2013-03-14 | 2016-08-24 | 上海医药工业研究院 | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 |
| KR102332836B1 (ko) | 2013-03-26 | 2021-12-01 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 발광 소자, 화합물, 유기 화합물, 디스플레이 모듈, 조명 모듈, 발광 장치, 표시 장치, 조명 장치 및 전자 기기 |
| CN105899511B (zh) * | 2013-09-11 | 2019-06-07 | 默沙东公司 | 三环促旋酶抑制剂 |
| PE20161083A1 (es) | 2014-01-31 | 2016-11-19 | Goldcorp Inc | Proceso para la separacion de al menos un sulfuro de metal a partir de una mena o concentrado de sulfuros mixtos |
| US10828329B2 (en) | 2015-06-05 | 2020-11-10 | Hema-Quebec | Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof |
| CN108431010B (zh) | 2015-12-25 | 2021-10-15 | 株式会社半导体能源研究所 | 化合物、发光元件、显示装置、电子设备及照明装置 |
| CN105461728A (zh) * | 2015-12-29 | 2016-04-06 | 中山大学 | 一种4-取代胺基-6-甲氧羰基苯并呋喃并[2,3-d]嘧啶类化合物及制备方法 |
| BR112018003417B1 (pt) * | 2016-06-22 | 2023-10-24 | Vanderbilt University | Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende |
| SG11201900515PA (en) | 2016-07-21 | 2019-02-27 | Biogen Ma Inc | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
| CN109862893B (zh) | 2016-11-07 | 2023-02-17 | 范德比尔特大学 | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
| US11008335B2 (en) | 2016-11-07 | 2021-05-18 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| US10927126B2 (en) | 2016-11-07 | 2021-02-23 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| CN110073510B (zh) | 2016-12-28 | 2022-07-19 | 株式会社半导体能源研究所 | 发光元件、有机化合物、发光装置、电子设备及照明装置 |
| JP2019006763A (ja) | 2017-06-22 | 2019-01-17 | 株式会社半導体エネルギー研究所 | 有機化合物、発光素子、発光装置、電子機器、および照明装置 |
| JP2021505581A (ja) | 2017-12-05 | 2021-02-18 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
| AU2020221247B2 (en) | 2019-02-12 | 2024-12-12 | Sumitomo Pharma America, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| CN112300082B (zh) * | 2019-07-26 | 2022-04-26 | 暨南大学 | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06220059A (ja) * | 1993-01-28 | 1994-08-09 | Tanabe Seiyaku Co Ltd | 縮合ピリミジン誘導体及びその製法 |
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| WO1997017329A1 (en) * | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| CA2239227C (en) | 1996-10-01 | 2007-10-30 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| JPH10175977A (ja) * | 1996-12-13 | 1998-06-30 | Takeda Chem Ind Ltd | 縮合インドール誘導体、その製造法及び用途 |
| EP1119567B1 (en) | 1998-10-08 | 2005-05-04 | AstraZeneca AB | Quinazoline derivatives |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| JP2003509497A (ja) * | 1999-09-21 | 2003-03-11 | アストラゼネカ アクチボラグ | キナゾリン化合物とそれらを含有する医薬組成物 |
| SK3822002A3 (en) | 1999-09-21 | 2002-10-08 | Astrazeneca Ab | Quinazoline derivatives, process for the preparation thereof and their use |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| NZ522696A (en) * | 2000-06-28 | 2004-08-27 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| JP2003183283A (ja) * | 2001-12-18 | 2003-07-03 | Takeda Chem Ind Ltd | 縮合インドール化合物、その製造法および用途 |
| KR101029281B1 (ko) * | 2001-12-24 | 2011-04-18 | 아스트라제네카 아베 | 오로라 키나제의 억제제로서 치환된 퀴나졸린 유도체 |
| GB0313766D0 (en) * | 2003-06-13 | 2003-07-23 | Xenova Ltd | Pharmaceutical compounds |
-
2004
- 2004-10-14 ES ES04795080T patent/ES2344007T3/es not_active Expired - Lifetime
- 2004-10-14 US US10/965,313 patent/US7326712B2/en not_active Expired - Fee Related
- 2004-10-14 PL PL04795080T patent/PL1678166T3/pl unknown
- 2004-10-14 WO PCT/US2004/033870 patent/WO2005037825A2/en not_active Ceased
- 2004-10-14 AU AU2004282179A patent/AU2004282179B2/en not_active Ceased
- 2004-10-14 EP EP04795080A patent/EP1678166B1/en not_active Expired - Lifetime
- 2004-10-14 DE DE602004022318T patent/DE602004022318D1/de not_active Expired - Lifetime
- 2004-10-14 SI SI200431206T patent/SI1678166T1/sl unknown
- 2004-10-14 PT PT04795080T patent/PT1678166E/pt unknown
- 2004-10-14 CA CA2542076A patent/CA2542076C/en not_active Expired - Fee Related
- 2004-10-14 DK DK04795080T patent/DK1678166T3/da active
- 2004-10-14 JP JP2006535644A patent/JP4845736B2/ja not_active Expired - Fee Related
- 2004-10-14 AT AT04795080T patent/ATE437872T1/de active
-
2005
- 2005-03-29 US US11/092,809 patent/US7326713B2/en not_active Expired - Fee Related
- 2005-03-29 US US11/092,168 patent/US7312226B2/en not_active Expired - Fee Related
- 2005-03-29 US US11/092,863 patent/US7335662B2/en not_active Expired - Fee Related
-
2009
- 2009-10-13 CY CY20091101047T patent/CY1110504T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1678166A2 (en) | 2006-07-12 |
| CA2542076A1 (en) | 2005-04-28 |
| US20050239794A1 (en) | 2005-10-27 |
| ATE437872T1 (de) | 2009-08-15 |
| PT1678166E (pt) | 2009-10-30 |
| SI1678166T1 (sl) | 2009-10-31 |
| EP1678166B1 (en) | 2009-07-29 |
| US7326713B2 (en) | 2008-02-05 |
| JP2007510627A (ja) | 2007-04-26 |
| WO2005037825A3 (en) | 2006-03-30 |
| US7335662B2 (en) | 2008-02-26 |
| US20050277658A1 (en) | 2005-12-15 |
| JP4845736B2 (ja) | 2011-12-28 |
| CY1110504T1 (el) | 2015-04-29 |
| AU2004282179B2 (en) | 2011-05-19 |
| US7312226B2 (en) | 2007-12-25 |
| WO2005037825A2 (en) | 2005-04-28 |
| AU2004282179A1 (en) | 2005-04-28 |
| ES2344007T3 (es) | 2010-08-16 |
| US7326712B2 (en) | 2008-02-05 |
| CA2542076C (en) | 2013-02-26 |
| DK1678166T3 (da) | 2009-11-09 |
| US20050239793A1 (en) | 2005-10-27 |
| US20050227992A1 (en) | 2005-10-13 |
| DE602004022318D1 (de) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1678166E (pt) | Inibidores de proteína-quinase | |
| GB0112348D0 (en) | Compounds | |
| DE602004007239D1 (de) | 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| MY140872A (en) | 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MY138352A (en) | Benzothiazole derivatives | |
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| SG149033A1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| YU59602A (sh) | Aril fuzionisana azapoliciklična jedinjenja | |
| MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| EA200600973A1 (ru) | ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 | |
| MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
| SE0202429D0 (sv) | Novel Compounds | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| MXPA05011207A (es) | Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo). | |
| PL1682528T3 (pl) | Pochodne benzo[b][1,4]dioksepiny | |
| MX2010001020A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. | |
| MY133527A (en) | Isoquinoline derivatives | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| TWI264437B (en) | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |